Merck Intrinsic Value Calculator – Dow Jones Industrial Average Falls Over 100 Points Amid Losses of Merck and Walmart Shares
July 13, 2023
🌧️Trending News
On Friday, the Dow Jones Industrial Average (DJIA) is trading lower, with losses in Merck ($NYSE:MRK) and Walmart shares leading the way and contributing to a nearly 100-point drop. Merck & Co., Inc., commonly known as Merck, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world. It is a publicly-traded company listed on the New York Stock Exchange (NYSE) and is part of the Dow Jones Industrial Average. Merck is a research-driven company that develops innovative medicines, vaccines, and biologic therapies to treat and prevent diseases. The company is focused on researching and developing treatments for cancer, infectious diseases, diabetes, and other health-related areas.
Additionally, Merck’s products span multiple therapeutic areas, including cardiovascular, gastrointestinal, neuroscience, infectious diseases, respiratory, and hematology-oncology. With its strong research and development capabilities, Merck is at the forefront of the industry in developing products to help patients live longer and healthier lives.
Price History
Merck_and_Walmart_Shares”>Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Merck. More…
| Total Revenues | Net Income | Net Margin |
| 57.87k | 13.03k | 23.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Merck. More…
| Operations | Investing | Financing |
| 15.67k | -6.15k | -8.09k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Merck. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 107.8k | 60.89k | 18.46 |
Key Ratios Snapshot
Some of the financial key ratios for Merck are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.4% | 8.7% | 28.0% |
| FCF Margin | ROE | ROA |
| 19.5% | 21.8% | 9.4% |
Analysis – Merck Intrinsic Value Calculator
GoodWhale has performed an analysis of MERCK‘s financials, and our proprietary Valuation Line has yielded an intrinsic value of MERCK’s shares to be around $93.7. This suggests that the current trading price of MERCK shares at $110.0 is a fair price, albeit one that is overvalued by 17.4%. We recommend that investors keep a watchful eye on the stock as they may want to consider buying or selling depending on any changes in the market. More…
Peers
In the pharmaceutical industry, Merck & Co Inc is up against some stiff competition. Sanofi SA, Roche Holding AG, and TherapeuticsMD Inc are all major players in the industry. While each company has its own strengths and weaknesses, they all compete against each other to bring new and innovative drugs to market.
– Sanofi SA ($LTS:0O59)
As of 2022, Sanofi SA has a market capitalization of 102.29 billion euros and a return on equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and is one of the world’s largest pharmaceutical companies. Sanofi is a diversified company, with operations in several therapeutic areas, including diabetes, vaccines, rare diseases, multiple sclerosis, oncology, immunology, and cardiovascular.
– Roche Holding AG ($LTS:0TDF)
Roche Holding AG, a Swiss multinational healthcare company, has a market cap of 270.34B as of 2022. The company’s Return on Equity is 47.83%. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. The company provides medicines and diagnostic tests that enable personalized health care for patients.
– TherapeuticsMD Inc ($NASDAQ:TXMD)
TherapeuticsMD Inc. is a biopharmaceutical company, which focuses on developing and commercializing products for the health and well-being of women. It offers products in various therapeutic areas, such as Menopause, Osteoporosis, Chronic Vulvar and Vaginal Atrophy, and other health conditions related to hormone deficiency and imbalances. The company was founded by Robert G. Finizio, George S. Paletta, and Douglas S. Leighton in 2010 and is headquartered in Boca Raton, FL.
Summary
MERCK is a stock that has been underperforming recently, evidenced by its loss leading the Dow Jones Industrial Average’s nearly 100-point drop. The company’s stock has lost value and is trading lower on Friday. This has been a common trend for MERCK in recent months, pointing to concerns by investors regarding the company’s performance. Analysts recommend caution when investing in MERCK as the stock is showing signs of underperformance and there is no clear indication that the trend will reverse in the near future.
